EP1725230A1 - Derives de methimazole et thiones cycliques tautomeres pour inhiber l'adhesion cellulaire - Google Patents

Derives de methimazole et thiones cycliques tautomeres pour inhiber l'adhesion cellulaire

Info

Publication number
EP1725230A1
EP1725230A1 EP04821836A EP04821836A EP1725230A1 EP 1725230 A1 EP1725230 A1 EP 1725230A1 EP 04821836 A EP04821836 A EP 04821836A EP 04821836 A EP04821836 A EP 04821836A EP 1725230 A1 EP1725230 A1 EP 1725230A1
Authority
EP
European Patent Office
Prior art keywords
vcam
cell adhesion
alkyl
tnf
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04821836A
Other languages
German (de)
English (en)
Other versions
EP1725230A4 (fr
Inventor
Leonard D. Kohn
Douglas Goetz
Norikazu Hari
Chris Lewis
Cesidio Giuliani
Giorgio Napolitano
Nilesh Dagia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intherthyr Corp
Original Assignee
Intherthyr Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intherthyr Corp filed Critical Intherthyr Corp
Publication of EP1725230A1 publication Critical patent/EP1725230A1/fr
Publication of EP1725230A4 publication Critical patent/EP1725230A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to novel compounds and methods of use for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies.
  • This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies.
  • Cell adhesion is a process by which cells associate with each other, migrate towards a specific target or localize within the extra-cellular matrix. As such, cell adhesion constitutes one of the fundamental mechanisms underlying numerous biological phenomena. For example, cell adhesion is responsible for the adhesion of hematopoietic cells to endothelial cells and the subsequent migration of those hematopoietic cells out of blood vessels and to the site of injury. Cell adhesion plays a role in pathological inflammation and immune reactions in mammals. [0004] Adhesion mediated by VCAM-1 and other endothelial cell surface receptors is associated with a number of inflammatory responses.
  • activated vascular endothelial cells express molecules that are adhesive for leukocytes.
  • the mechanics of leukocyte adhesion to endothelial cells involves, in part, the recognition and binding of cell surface receptors on leukocytes to the corresponding cell surface molecules on endothelial cells. Once bound, the leukocytes migrate across the blood vessel wall to enter the injured site and release chemical mediators to combat infection.
  • Inflammatory brain disorders such as experimental autoimmune encephalomyelitis (EAE), multiple sclerosis (MS) and meningitis, are examples of central nervous system disorders in which the endothelium/leukocyte adhesion mechanism results in destruction to otherwise healthy brain tissue.
  • EAE experimental autoimmune encephalomyelitis
  • MS multiple sclerosis
  • M multiple sclerosis
  • meningitis are examples of central nervous system disorders in which the endothelium/leukocyte adhesion mechanism results in destruction to otherwise healthy brain tissue.
  • BBB blood brain barrier
  • the leukocytes release toxic mediators that cause extensive tissue damage resulting in impaired nerve conduction and paralysis.
  • tissue damage also occurs via an adhesion mechanism resulting in migration or activation of leukocytes.
  • an adhesion mechanism resulting in migration or activation of leukocytes.
  • Other pathologies mediated by an adhesion mechanism include, by way of example, asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, tissue transplantation and tumor metastasis.
  • ECAMs Endothelial cell adhesion molecules
  • VCAM-1 Endothelial cell adhesion molecules
  • ICAM-1 Endothelial cell adhesion molecules
  • VCAM-1 is present in a localized fashion on aortic endothelium that overlies early foam cell lesions (1) and is increased on endothelium in models of colitis (4).
  • a promising therapeutic approach for treating pathological inflammation is, therefore, to reduce aberrant leukocyte adhesion to the endothelium via suppression of ECAM expression (5).
  • ECAM expression is influenced by the cytoldne milieu in which the endothelial cells reside. Indeed, treating cultured endothelial cells with the pro-inflammatory cytoldne TNF- ⁇ for 4 hrs. elicits expression of E-selectin, VCAM-1 and ICAM-1 (6).
  • the cytoldne dependent ECAM induction is regulated at the gene level by the activity of transcription factors such as nuclear factor- ⁇ B (NF- ⁇ B), activator protein- 1 (AP-1), specificity protein- 1 (SP-1), interferon regulatory factor-1 (tRF-1) and GATA.
  • transcription factors such as nuclear factor- ⁇ B (NF- ⁇ B), activator protein- 1 (AP-1), specificity protein- 1 (SP-1), interferon regulatory factor-1 (tRF-1) and GATA.
  • the E- selectin promoter has binding sites for NF- ⁇ B (7)
  • the VCAM-1 promoter has binding sites for NF- ⁇ B, AP-1, SP-1, IRF-1 and GATA (8-11)
  • the ICAM- 1 promoter has functional binding sites for NF- ⁇ B and AP-1 (12, 13).
  • Some of these transcription factors e.g. NF- ⁇ B
  • the active/induced transcription factors ligate to their respective binding sites leading to gene transcription.
  • methimazole acts as a transcriptional inhibitor of abnormally increased MHC Class I and Class II gene expression (26-29) and mimics the effect of a Class I l ⁇ iockout in preventing autoimmune disease (30).
  • methimazole may also affect ECAM expression and thus could be a potential anti-inflammatory compound. Specifically, it has been reported that (a) Graves' disease patients treated with methimazole have reduced levels of circulating soluble E-selectin and soluble VCAM-1 (31) and (b) methimazole decreases colonic mucosal damage in a rat model of experimental colitis (32).
  • VCAM-1 -dependent cell adhesion There remains a need for inhibitors of VCAM-1 -dependent cell adhesion. Such compounds would provide useful agents for treatment, prevention or suppression of various pathologies involving VCAM-1 mediated cell adhesion.
  • methimazole derivatives and tautomeric cyclic thiones are effective as anti-inflammatories, in the case of inflammatory symptoms of very different cause, to prevent, reduce or suppress the undesired or harmful sequence of the inflammation. They are used, for example, for the treatment of arthritis, rheumatoid arthritis, polyarthritis, inflammatory bowel disease (ulcerative colitis, Crohn's disease), systemic lupus erythematosus, inflammatory diseases of the central nervous system (e.g., multiple sclerosis), or asthma or allergies (e.g., allergies of the delayed type (type IV allergy)).
  • compounds of the present invention are suitable for cardioprotection, for stroke protection and for the secondary prophylaxis of stroke and for the treatment of cardiovascular diseases, atherosclerosis, myocardial infarct, myocardial reinfarct, acute coronary syndrome, stroke, restenoses, diabetes, damage to organ transplants, immune diseases, autoimmune diseases, tumor growth or tumor metastasis in various malignancies, malaria and other diseases where a blocking of abnormally increased expression of VCAM-1 and/or an influencing of the leukocyte activity appears appropriate for prevention, alleviation or cure.
  • a preferred use is the prevention of inflammatory bowel disease and macro- or microvascular complications of Types I or II diabetes, e.g., myocardial infarct or of myocardial reinfarct or nephropathy.
  • the present invention relates to novel compounds and methods of use for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies.
  • This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies.
  • the compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents.
  • methimazole derivatives and tautomeric cyclic thiones have the ability to inhibit the adhesion and the migration of leukocytes (e.g., the adhesion of monocytes to endothelial cells), which is mediated by VCAM-1 adhesion mechanism.
  • methimazole derivatives and tautomeric cyclic thiones and their physiologically tolerable salts and derivatives are generally suitable for the treatment (i.e., for the therapy and prophylaxis) of diseases that are based on the interaction between VCAM-1 and VCAM-1 ligands (e.g.
  • VLA-4 or 0:4/37) or can be influenced by an inhibition of this interaction hi particular, the methimazole derivatives and tautomeric cyclic thiones are suitable for the treatment of diseases that are caused at least partly by an undesired extent of leukocyte adhesion and/or leukocyte migration or are connected therewith, and for whose prevention, alleviation or cure the adhesion and/or migration of leukocytes should be decreased.
  • the present invention also relates to the methimazole derivatives and tautomeric cyclic thiones and/or their physiologically acceptable salts and/or derivatives for the inhibition of the adhesion and/or migration of leukocytes or for the inhibition of abnormally increased VCAM-1 expression, e.g. that induced by cytokines such as TNF-o:.
  • the present invention relates to the use of the methimazole derivatives and tautomeric cyclic thiones and/or their physiologically acceptable salts and/or derivatives for the preparation of pharmaceuticals thereof, i.e., of pharmaceuticals for the treatment of diseases, wherein the leukocyte adliesion and/or leukocyte migration shows an undesired extent, or for the treatment of diseases, wherein VCAM-1 - dependent adhesion processes play a role, and to the use of the methimazole derivatives and tautomeric cyclic thiones and/or their physiologically acceptable salts and/or derivatives in the treatment of diseases of this type.
  • the present invention provides for methods for reducing aberrant leukocyte-endothelial adhesion during pathological inflammation by inhibiting endothelial cell adhesion molecule (ECAM) expression at the transcriptional level.
  • ECAM endothelial cell adhesion molecule
  • the present invention provides for methods of using methimazole derivatives to modulate TNF- ⁇ - induced ECAM (e.g., E-selectin, ICAM-1 and VCAM-1) expression and consequent monocytic cell (U-937) adhesion to human aortic endothelial cells (HAEC).
  • these novel compounds, compositions and methods are advantageously used to treat inflammatory and immune diseases.
  • the present invention also provides methods for preparing the compounds of this invention and intermediates useful in those methods.
  • the present invention provides for the use of methimazole (l-methyl-2-mercaptoimidazole) and its derivatives.
  • the present invention provides for the use of a prodrag form of methimazole, known as carbimazole (neomercazole) and its derivatives.
  • the present invention provides for the use of a composition containing one or more of the compounds selected from the group consisting of methimazole, metronidazole, 2-mercaptoimidazole, 2- mercaptobenzimidazole, 2-mercapto-5-nitrobenzimidazole, 2-mercapto-5- methylbenzimidazole, s-methylmethimazole, n-methylmethimazole, 5- methylmethimazole, 5-phenylmethimazole, and l-methyl-2-thiomethyl- 5(4)nitroimidazole.
  • 5-phenylmethimazole is used.
  • the present invention provides for the use of phenyl methimazole (compound 10; C-10) and its derivatives.
  • Compounds of this invention may be synthesized using any conventional technique. Preferably, these compounds are chemically synthesized from readily available starting materials.
  • the compounds of this invention may also be modified by appending appropriate functionalities to enhance selective biological properties.
  • modifications are known in the art and include those which increase biological penetration into a given biological system (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.
  • the term "patient” refers to mammals, including humans.
  • the term “cell” refers to mammalian cells, including human cells.
  • the activities and VCAM-1 specificities of the compounds according to this invention may be determined using in vitro and in vivo assays.
  • the cell adhesion inhibitory activity of these compounds may be measured by determining the concentration of inhibitor required to block the binding of VCAM-1 -expressing cells to VCAM-1 ligand (e.g., VLA-4) expressing cells (e.g., monocytes, lymphocytes).
  • VCAM-1 ligand e.g., VLA-4
  • VCAM-1 ligand e.g., VLA-4
  • VCAM-1 ligand e.g., VLA-4
  • monocytes e.g., monocytes, lymphocytes
  • microtiters wells are coated with cells (e.g., endothelial cells), which can express VCAM-1.
  • a cytokine e.g., TNF- ⁇
  • the test compound may be added first and allowed to incubate with the coated wells containing endothelial cells prior to the addition of the cytokine.
  • the cells are allowed to incubate in the wells for at least 2 hrs.
  • appropriately labeled VCAM-1 ligand-expressing cells e.g., monocytes, lymphocytes
  • VCAM-1 ligand-expressing cells e.g., monocytes, lymphocytes
  • the wells are washed. Inhibition of binding is measured by quantitating the fluorescence or radioactivity bound to the VCAM-1 expressing cells in the plate for each of the various concentrations of test compound, as well as for controls containing no test compound.
  • VCAM- 1 -expressing cells that may be utilized in this assay include nonimmune target tissue cells, endothelial cells, and epithelial cells.
  • the VCAM-lligand expressing cells e.g., monocytes, lymphocytes
  • used in this assay may be fluorescently or radioactively labeled.
  • a direct binding assay may also be employed to quantitate the inhibitory activity of the compounds of this invention.
  • VCAM- 1 -specific inhibitors may be further characterized in in vivo assays.
  • One such assay tests the effects of inhibitors on VCAM-1 expression and leukocyte adhesion in well-established in vivo models of pathological inflammation (e.g., inflamed mesenteric endothelium in murine model of chronic inflammation (i.e., colitis); isolated carotid arteries of apolipoprotein E-deficient (apoE -/-) mice with developing atherosclerotic lesions).
  • pathological inflammation e.g., inflamed mesenteric endothelium in murine model of chronic inflammation (i.e., colitis); isolated carotid arteries of apolipoprotein E-deficient (apoE -/-) mice with developing atherosclerotic lesions).
  • the compounds of the present invention may be used in the form of pharmaceutically acceptable salts derived from inorganic or organic acids and bases. Included among such acid salts are the following: acetate, adipate, alginate, aspartate, benzoate benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2- naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, pers
  • Base salts include ammonium salts, alkali metal salts, such as sodium and potassium salts, alkaline earth metal salts, such as calcium and magnesium salts, salts with organic bases, such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth.
  • the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates, such as dimethyl, diethyl, dibutyl and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides, such as benzyl and phenethyl bromides and others. Water or oil-soluble or dispersible products are thereby obtained.
  • lower alkyl halides such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides
  • dialkyl sulfates such as dimethyl, diethyl, dibutyl and diamyl sulfates
  • long chain halides such
  • the compounds of the present invention may be formulated into pharmaceutical compositions that may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
  • parenteral as used herein includes subcutaneous, intravenous, intraperitoneal, intramuscular, intra-articular, intra- synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.
  • compositions of this invention comprise any of the compounds of the present invention, or pharmaceutically acceptable salts thereof, together with any pharmaceutically acceptable carrier.
  • carrier includes acceptable adjuvants and vehicles.
  • Pharmaceutically acceptable carriers that may be used in the pharmaceutical compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers,
  • compositions may comprise liposomes or drug carriers made lipids or polymeric particles, including biodegradable polymers, or targeted delivery applications, e.g., coupling to antibodies. They include solubilization with dimethylsulfoxide before dilution to final useful concentrations.
  • the pharmaceutical compositions may be in the form of a sterile injectable preparation, for example a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butanediol or dimethyl sulfoxide.
  • a non-toxic parenterally-acceptable diluent or solvent for example as a solution in 1,3-butanediol or dimethyl sulfoxide.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or di-glycerides.
  • Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of mjectables, as do natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
  • oils such as olive oil or castor oil, especially in their polyoxyethylated versions.
  • These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as Ph. Helv or similar alcohol.
  • compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions.
  • carriers which are commonly used include lactose and corn starch.
  • Lubricating agents such as magnesium stearate, are also typically added.
  • useful diluents include lactose and dried co ⁇ istarch.
  • aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
  • compositions of this invention may be administered in the form of suppositories for rectal administration.
  • suppositories for rectal administration.
  • suppositories can be prepared by mixing the agent with a suitable non-irritating excipient which is solid at room temperature but liquid at the rectal temperature and therefore will melt in the rectum to release the drag.
  • suitable non-irritating excipient include cocoa butter, beeswax and polyethylene glycols.
  • compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.
  • Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.
  • the pharmaceutical compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers.
  • Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water.
  • the pharmaceutical compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers.
  • Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
  • the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with our without a preservative such as benzylalkonium chloride.
  • the pharmaceutical compositions may be formulated in an ointment such as petrolatum.
  • the pharmaceutical compositions of this invention may also be administered by nasal aerosol or inhalation through the use of a nebulizer, a dry powder inhaler or a metered dose inhaler.
  • compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
  • the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated, and the particular mode of administration. It should be understood, however, that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drag combination, and the judgment of the treating physician and the severity of the particular disease being treated. The amount of active ingredient may also depend upon the therapeutic or prophylactic agent, if any, with which the ingredient is co-administered.
  • the dosage and dose rate of the compounds of this invention effective to prevent, suppress or inhibit cell adhesion will depend on a variety of factors, such as the nature of the inhibitor, the size of the patient, the goal of the treatment, the nature of the pathology to be treated, the specific pharmaceutical composition used, and the judgment of the treating physician. Dosage levels of between about 0.001 and about 100 mg/kg body weight per day, preferably between about 0.1 and about 10 mg/kg body weight per day of the active ingredient compound are useful.
  • compositions containing a compound of this invention may also comprise an additional agent selected from the group consisting of corticosteroids, bronchodilators, antiasthmatics (mast cell stabilizers), anti-inflammatories, antirheumatics, immunosuppressants, antimetabolites, immunonodulators, antipsoriatics, antibiotics, and antidiabetics.
  • an additional agent selected from the group consisting of corticosteroids, bronchodilators, antiasthmatics (mast cell stabilizers), anti-inflammatories, antirheumatics, immunosuppressants, antimetabolites, immunonodulators, antipsoriatics, antibiotics, and antidiabetics.
  • Also included within this group are compounds such as theophylline, sulfasalazine and ammosahcylates (antiinflammatories); cyclosporin, FK-506, and rapamycin (immunosuppressants); cyclophosphamide and methotrexate (antimetabolites); and interferons (immunomodulators).
  • the invention provides methods for preventing, inhibiting or suppressing cell adhesion-associated inflammation and cell adhesion-associated immune or autoimmune responses.
  • VCAM-1- associated cell adhesion plays a central role in a variety of inflammatory, immune and autoimmune diseases.
  • inhibition of cell adhesion by the compounds of this invention may be utilized in methods of treating or preventing inflammatory, immune and autoimmune diseases.
  • the diseases to be treated with the methods of this invention are selected from asthma, arthritis, psoriasis, transplantation rejection, multiple sclerosis, diabetes, inflammatory bowel disease, and inflammatory/immune diseases related to activation of the innate immune system such as endo toxic shock.
  • These methods may employ the compounds of this invention in a monotherapy or in combination with an anti-inflammatory or immunosuppressive agent.
  • Such combination therapies include administration of the agents in a single dosage form or in multiple dosage forms administered at the same time or at different times.
  • FIG. 1 A methimazole derivative (C-10) significantly inhibits short term (2 - 4 hr.) TNF- ⁇ induced expression of VCAM-1 but has little to no effect on TNF- ⁇ induced E-selectin and ICAM-1 expression.
  • ELISA ELISA
  • mRNA 2
  • TNF- ⁇ activated HAEC in the absence or presence of C-10, are determined by ELISA and Northern blot analysis respectively.
  • A The level of absorbance indicated by optical density (O.D. at 450 nm) correlates with the level of a given ECAM protein (e.g.
  • E-selectin on the HAEC. All values are mean +/- std. deviation of triplicate wells. Results presented are representative of a typical experiment done at least 3 times. A mAb to LFA-1 (TS1/22) served as a negative control.
  • B RNA isolated from HAEC was subjected to Northern blot analyses using appropriate probes for E-selectin, ICAM-1 and VCAM-1. G3PDH probe was used as the loading control. Results presented are typical of 3 separate experiments.
  • TNF- ⁇ activation indicates activation of HAEC with TNF- ⁇ (+) or no activation (-) prior to the assay. Treatment indicates treatment of HAEC with C-10, DMSO or no treatment (-) during activation with TNF- ⁇ . * indicates p ⁇ 0.001).
  • FIG. 1 C-10 significantly inhibits 24 hr. TNF- ⁇ induced expression of VCAM-1 and E-selectin but has no effect on ICAM-1 expression.
  • A The level of absorbance indicated by optical density (O.D. at 450 nm) correlates with the level of a given ECAM protein (e.g. E-selectin) on the HAEC. All values are mean +/- std. deviation of triplicate wells.
  • Results presented are representative of a typical experiment done at least 3 times.
  • a mAb to LFA-1 (TS1/22) served as a negative control and gave results (data not shown) similar to that shown in Fig. 1 A.
  • B RNA isolated from HAEC was subjected to Northern blot analyses using appropriate probes for E-selectin, ICAM-1 and VCAM-1. G3PDH probe was used as a loading control. Results presented are typical of 3 separate experiments.
  • TNF- ⁇ activation indicates activation of HAEC with TNF- ⁇ (+) or no activation (-) prior to the assay.
  • Treatment indicates treatment of HAEC with C-10, DMSO or no treatment (-) during activation with TNF- ⁇ . * indicates p ⁇ 0.001)
  • FIG. 10 has a modest effect on U937 adhesion to 4 hr.
  • TNF- ⁇ activated HAEC and a dramatic effect on U937 adhesion to 24 hr.
  • HAEC are treated for 4 hrs. (A) or 24 hrs. (B) with TNF- ⁇ in the absence or presence of C-10.
  • HAEC are pre-treated with mAb prior to use in adhesion assays.
  • U937 cells are perfused over the HAEC and the number of U937 cells adherent to the HAEC at the end of 2.5 minutes of flow determined.
  • TNF- ⁇ activation indicates activation of HAEC with TNF- ⁇ (+) or no activation (-) for 4 hrs. (A) or 24 hrs. (B) prior to the adhesion assay. Treatment indicates treatment of HAEC with 0.5 mM (A) or 0.1 mM (B) C-10, DMSO or no treatment (-) during activation with TNF- ⁇ .
  • mAb indicates pre-treatment of HAEC with a mAb to E-selectin, HEL3/2 (E), a mAb to VCAM-1, 51-10C9 (V), a combination of mAbs to VCAM-1, 51-10C9, and E-selectin, HEL3/2 (V+E) or no pre-treatment (-) after the other treatments but prior to the adhesion assay.
  • Shear Stress 1.8 dynes/cm 2 ; n > 3; error bars represent SEM; # indicates p ⁇ 0.05)
  • FIG. 4 C-10 inhibits TNF- ⁇ induced increase in VCAM-1 promoter activity in HAEC.
  • Left The locations of the binding sites for various transcription factors known to play a role in TNF- ⁇ induced human VCAM-1 expression are used as a template to create -1641/+12, -288/+12, - 228/+12 and -85/+12 bp constructs.
  • HAEC are transfected for 24 hrs. with 400 ng of the constructs indicated on the left or pGL3 basic luciferase reporter vector. All HAEC are also transfected with pl RL-TK ( t-) vector that contains Renilla luciferase (R/wc) as an "internal" transfection control.
  • HAEC are treated for 6 hrs. with 10 ng/ml TNF- ⁇ in the absence or presence
  • VCAM-1 promoter (A) Probe sequences used in EMS A. Overhead line indicates the IRF-1 binding site. Lower case letters indicate the mutated
  • EMSA are performed with P-labeled IRF-1 probe and 3 ⁇ g of nuclear
  • TNF- ⁇ (+) or no activation (-) prior to the assay indicates treatment of HAEC with 0.5 mM C-10, 1 mM C-10, or DMSO (DMSO) or no treatment (-) during activation with TNF- ⁇ .
  • Competitor indicates absence (-) or presence of 100 fold molar excess of unlabeled VCAM-1 IRF-1 probe (VCAM-1 IRF wild) or VCAM-1 IRF-1 mutant probe (VCAM L F Mutant) or consensus IRF-1 probe (Cons. IRF) or consensus NF- ⁇ B probe (cons. NF- KB) or 2 ⁇ g antibody to IRF-1 (IRF-1 Ab)).
  • RNA isolated from HAEC was subjected to Northern blot analyses using IRF-1 probe. Ethidium bromide stained rRNA was the loading control.
  • B Whole cell lysates of HAEC are subjected to Western blot analysis using IRF-1 antibody. Ponceau S staining of blots after transfer revealed equivalent loading of total protein (data not shown).
  • TNF- ⁇ indicates activation of HAEC with 10 ng/ml TNF- ⁇ (+) or no activation (-) prior to the assay.
  • C-10 indicates treatment of HAEC with 0.5 mM or 1 mM C-10 or DMSO (-) during activation with TNF- ⁇ .
  • the present invention also provides for the use of methimazole derivatives and tautomeric cyclic thione compounds that specifically inhibit the binding of VCAM-1. These compounds are useful for inhibition, prevention and suppression of VCAMl -mediated cell adhesion and pathologies associated with that adhesion, such as inflammation and immune reactions.
  • the compounds of this invention may be used alone or in combination with other therapeutic or prophylactic agents to inhibit, prevent or suppress cell adhesion.
  • This invention also provides pharmaceutical formulations containing these VCAM-1 -mediated cell adhesion inhibitors arid methods of using the compounds and compositions of the invention for inhibition of cell adhesion. As used herein, the following terms shall have the definitions given below.
  • safe and effective amount means a sufficient amount of pharmaceutically active compound to effect the inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies.
  • the required dosage of a pharmaceutically active agent or of the pharmaceutical composition containing that active agent will vary with the severity of the condition being treated, the duration of the treatment, the nature of adjunct treatment, the age and physical condition of the patient, the specific active compound employed, and like considerations discussed more fully hereinafter, hi arriving at the "safe and effective amount" for a particular compound, these risks must be taken into consideration, as well as the fact that the compounds described herein provide pharmaceutical activity at lower dosage levels than conventional methimazole compounds.
  • “Pharmaceutically-acceptable” shall mean that the pharmaceutically active compound and other ingredients used in the pharmaceutical compositions and methods defined herein are suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio.
  • the term "administration" of the pharmaceutically active compounds and the pharmaceutical compositions defined herein includes systemic use, as by injection (especially parenterally), intravenous infusion, suppositories and oral administration thereof, as well as topical application of the compounds and compositions. Oral administration is particularly preferred in the present invention.
  • “Ameliorate” or “amelioration” means a lessening of the detrimental effect or severity of the cell adhesion disorder in the subject receiving therapy, the severity of the response being determined by means that are well known in the art.
  • adhesion disorder of cell adhesion means atypical cell adhesion leading to pathologies, including, without limitation, reperfusion injury following ischemia, atherosclerosis, inflammatory bowel disease (Crohns' disease and ulcerative colitis), thermal injury (burns), arthritis, asthma, organ transplantation (host vs. graft and graft vs.
  • compositions and methods of this invention means that various other compatible drugs and medicaments, as well as inert ingredients, can be conjointly employed in the pharmaceutical compositions and methods of this invention, as long as the defined pharmaceutically active compounds and carriers are used in the manner disclosed.
  • comprising thus encompasses and includes the more restrictive terms “consisting of and “consisting essentially of.
  • patient is intended to encompass any mammal, animal or human, which may benefit from treatment with the compounds, compositions and methods of the present invention.
  • Treat,” “treating,” “treatment,” and “therapy” as used herein refer to any curative therapy, prophylactic therapy, ameliorative therapy and preventative therapy.
  • compositions which comprise the present invention are capable of being commingled without interacting in a manner which would substantially decrease the efficacy of the pharmaceutically active compound under ordinary use conditions.
  • the pharmaceutical compositions of the present invention comprise specifically-defined methimazole derivatives and tautomeric cyclic thiones, used in a safe and effective amount, together with a pharmaceutically- acceptable carrier.
  • methimazole derivatives used in the compositions of the present invention are those having the following structural formulae:
  • Y is selected from H, CI -C4 alkyl CI -C4 substituted alkyl, — NO , and the phenyl moiety:
  • R 1 is selected from H, -OH, halogens (F, CI, Br or I), CrC 4 alkyl, Ci- C 4 substituted alkyl, CrC 4 ester or C C 4 substituted ester;
  • R 2 is selected from H, Ci-C 4 alkyl or C !
  • R 3 is selected from H, C C 4 alkyl, CrC 4 substituted alkyl or -CH 2 Ph (wherein Ph is phenyl);
  • R 4 is selected from H, C C 4 alkyl or -C 4 substituted alkyl;
  • X is selected from S or O;
  • Z is selected from -SR 3 , -OR 3 , S(O)R 3 or C 1 -C 4 alkyl; and wherein at least two of the R 2 and R 3 groups on said compound are C 1 -C 4 alkyl when Y is not a phenyl moiety, and at least one Y is -NO 2 when Z is alkyl; together with a pharmaceutically-acceptable carrier.
  • Y is preferably H, the phenyl moiety or ⁇ NO 2 , and is most preferably H or the phenyl moiety
  • R 1 is selected from H, -OH, halogens (F, CI, Br and I), C 1 -C 4 alkyl, C C 4 substituted alkyl, C 1 -C 4 ester and C C 4 substituted ester; preferably R 1 is H, -OH, halogen, -OOC CH M (where M is H or a halogen); and is most preferably H.
  • R 2 is selected from H, C C 4 alkyl and C C 4 substituted alkyl; preferably one or both of the R 2 groups is methyl.
  • substituted alkyl or “substituted ester” is intended to include alkyl, aryl or ester groups which are substituted in one or more places with hydroxyl or alkoxyl groups, carboxyl groups, halogens, nitro groups, amino or acylamino groups, and mixtures of those moieties.
  • Preferred "substituted alkyl” groups are C C 4 hydroxyl or alkoxyl groups, as well as groups substituted with halogens.
  • R groups in the above formulae are selected from H, C C 4 alkyl, Ci-C 4 substituted alkyl and -CH Ph (wherein Ph is phenyl); in preferred compounds, R is H or CrC 4 alkyl; most preferably R is CrC 4 alkyl, particularly methyl. R 4 is selected from H, -C 4 alkyl and -C 4 substituted alkyl, and preferably is H.
  • X may be S or O, and is preferably S.
  • Z is selected from d-C 4 alkyl, -SR 3 , -S(O)R 3 and -OR 3 , is preferably -SR 3 , -OR 3 , and -S(O)R 3 ; most preferably -SR 3 and -OR 3 ; and particularly - SR 3 .
  • at least two of the R 2 and R 3 groups on the compound must be C 1 -C 4 alkyl when Y is not a phenyl moiety. Further, at least one of the Y groups should be -NO ) , when Z is Cj:-C 4 alkyl.
  • Compounds useful in the present invention include the tautomeric cyclic thiones, disclosed in Kjellin and Sandstrom, Acta Chemica Scandanavica 23: 2879-2887 (1969), incorporated herein by reference, having the formulae
  • R ,5p R° CH 3 , CH 3 ; Ph, H; H, Ph
  • R 7 H, CH 3
  • compositions include those having the formulae:
  • R 10 is selected from H. NO 2 , Ph, 4-HOPh and 4-m-Ph (wherein m is F, CI, Br, or I).
  • a particularly preferred subset of the pharmaceutical compounds defined herein are those wherein one of the Y groups is the phenyl moiety defined above. These compounds have the following formulae:
  • Y is selected from H, C C 4 alkyl and - substituted alkyl, and is preferably H.
  • R 1 is selected from H, -OH, halogens (F, CI, Br and I), d-C 4 alkyl, C C 4 substituted alkyl, C C 4 ester, and C ⁇ -C 4 substituted ester, and is preferably H, -OH, halogen, -OOCCH 2 M (where) M is H or a halogen), and is not preferably H.
  • R 2 is selected from H, -C 4 alkyl and C ⁇ . -C 4 substituted alkyl, and it is preferred that at least one of the R 2 groups be methyl.
  • R 3 is selected from H, C Q alkyl, C C 4 substituted alkyl, and -CH 2 Ph; preferred R 3 moieties are H and methyl.
  • R 4 is selected from H, Ci-C 4 .alkyl and C 1 -C 4 substituted alkyl, and is preferably H.
  • X is selected from S and O, and is preferably S.
  • the Z moiety is selected from -SR 3 and -OR 3 , and is preferably -SR 3 .
  • Particularly preferred compounds are those having the structural formulae:
  • R 9 is selected from --OH, ⁇ M and ⁇ OOCCH 2 M; and M is selected
  • a representative methimazole derivative may be synthesized using the following procedure.
  • Appropriately substituted analogs of acetaldehyde are brominated in the 2-position by treatment with bromine and UV light, followed by formation of the corresponding diethylacetal using absolute ethanol.
  • the bromine is then displaced from this compound by treatment with anhydrous methylamine, or other suitable amine, in a sealed tube at about 120° for up to about 16 hours.
  • Table 1 Structure of Compounds.
  • the pharmaceutical compositions of the present invention comprise a safe and effective amount of one or more of the methimazole derivatives or tautomeric cyclic thione compounds (i.e., the active compounds).
  • Preferred compositions contain from about 0.01 % to about 25 % of the active compounds, with most preferred compositions containing from about 0.1% to about 10% of the active compounds.
  • the pharmaceutical compositions of the present invention may be administered in any way conventionally known, for example, intraperitoneally, intravenously, intramuscularly, or topically, although oral administration is preferred.
  • Preferred compositions are in unit dosage form, i.e., pharmaceutical compositions, which are available in apre- measured form suitable for single dosage administration without requiring that the individual dosage be measured out by the user, for example, pills, tablets or ampules.
  • compositions of the present invention additionally include a pharmaceutically-acceptable carrier compatible with the methimazole derivatives or tautomeric cyclic thiones described above.
  • the pharmaceutical compositions may contain, at their art accepted levels, additional compatible ingredients, such as additional pharmaceutical actives, excipients, formulational aids (e.g., tabletting aids), colorants, flavorants, preservatives, solubilizing or dispersing agents, and other materials well known to those skilled in the art.
  • additional compatible ingredients such as additional pharmaceutical actives, excipients, formulational aids (e.g., tabletting aids), colorants, flavorants, preservatives, solubilizing or dispersing agents, and other materials well known to those skilled in the art.
  • pharmaceutical carrier denotes a solid or liquid filler, diluent or encapsulating substance. These materials are well known to those skilled in the pharmaceutical arts.
  • substances which can serve as pharmaceutical carriers are sugars, such as lactose, glucose, and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; stearic acid; magnesium stearate; calcium sulfate; vegetable oils, such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil and oil of theobroma; polyols, such as propylene glycol, glycerine, sorbitol, mannitol, and polyethylene glycol; agar; alginic acid; pyrogen-free water; isotonic saline; and phosphate buffer solutions, as well as other non-toxic compatible substances used in pharmaceutical formulations.
  • sugars such as lactose, glucose, and sucrose
  • starches such as corn starch and potato starch
  • liposomes or drug carriers made lipids or polymeric particles, including biodegradable polymers, or targeted delivery applications, e.g., coupling to antibodies.
  • Wetting agents and lubricants such as sodium lauryl sulfate, as well as coloring agents, flavoring agents, tableting agents, and preservatives, can also be present. Formulation of the components into pharmaceutical compositions is done using conventional techniques.
  • the pharmaceutical carrier employed in conjunction with the pharmaceutical compositions of the present invention is used at a concentration sufficient to provide a practical size-to-dosage relationship.
  • the pharmaceutical carrier comprises from about 75% to about 99.99%, preferably from about 90% to about 99.9%, by weight of the total pharmaceutical composition.
  • the methimazole derivatives or tautomeric cyclic thiones defined in the present application may surprisingly be more soluble than methimazole in conventional carrier materials. This provides significant benefits in allowing greater flexibility in the formulation of pharmaceutical compositions containing those methimazole derivatives, and may allow the use of significantly lower doses of the active compound.
  • methimazole derivatives of the present invention are administered in a dosage range of from about 0.001 to about 100 milligrams, preferably from about 0.05 to about 50 milligrams, per day.
  • the pharmaceutical compositions of the present invention are administered such that appropriate levels of pharmaceutical active are achieved in the bloodstream.
  • the precise dosage level required in a given case will depend upon, for example, the particular methimazole derivative used, the nature of the disease being treated, and the size, weight, age and physical condition of the patient.
  • salts refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic or organic bases and inorganic or organic acids.
  • Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts.
  • Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2- diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isOpropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.
  • basic ion exchange resins such as
  • salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids.
  • acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid, and the like.
  • the compounds referred to herein are meant to also include the pharmaceutically acceptable salts.
  • the ability of the therapeutic compounds of the present invention to inhibit the actions of VCAM-1 malces them useful for preventing or reversing the symptoms, disorders or diseases induced by the binding of VCAM-1 to its various-ligands (e.g., VLA-4).
  • these compounds will inhibit rolling and cell adhesion processes including cell signaling, activation, migration, proliferation and differentiation.
  • another aspect of the present invention provides a method for the treatment (including prevention, alleviation, amelioration or suppression) of diseases or disorders or symptoms mediated by VCAM-1 binding, and cell adliesion and activation, which comprises administering to a mammal an effective amount of a compound of the present invention.
  • diseases, disorders, conditions or symptoms are for example (1) multiple sclerosis, (2) asthma, (3) allergic rhinitis, (4) allergic conjunctivitis, (5) inflammatory lung diseases, (6) rheumatoid arthritis, (7) septic arthritis, (8) type I or Type II diabetes and their macro- or microvascular complications, e.g.
  • nephropathy, stroke, or myocardial infarct (9) organ transplantation rejection, (10) restenosis, (11) autologous bone marrow transplantation, (12) inflammatory sequelae of viral infections, (13) myocarditis, (14) inflammatory bowel disease including ulcerative colitis and Crohn's disease, (15) certain types of toxic and immune-based nephritis, (16) contact dermal hypersensitivity, (17) psoriasis, (18) tumor metastasis, (19) thyroiditis, and (20) atherosclerosis.
  • the magnitude of prophylactic or therapeutic dose of the therapeutic compound of the present invention will, of course, vary with the nature of the severity of the condition to be treated and with the particular therapeutic compound of the present invention and its route of administration.
  • the daily dose range lie within the range of from about 0.001 mg to about 100 mg per kg body weight of a mammal, preferably 0.01 mg to about 50 mg per kg, and most preferably 0.1 to 10 mg per kg, in single or divided doses. On the other hand, it may be necessary to use dosages outside these limits in some cases.
  • a suitable dosage range is from about 0.001 mg to about 25 mg (preferably from 0.01 mg to about 1 mg) of a therapeutic compound of the present invention per kg of body weight per day and for cytoprotective use from about 0.1 mg to about 100 mg (preferably from about 1 mg to about 100 mg and more preferably from about 1 mg to about 10 mg) of the therapeutic compound of the present invention per kg of body weight per day.
  • a suitable dosage range is, e.g. from about 0.01 mg to about 100 mg of the therapeutic compound of the present invention per kg of body weight per day, preferably from about 0.1 mg to about 10 mg per kg and for cytoprotective use from 0.1 mg to about 100 mg (preferably from about 1 mg to about 100 mg and more preferably from about 10 mg to about 100 mg) of a therapeutic compound of the present invention per kg of body weight per day.
  • ophthalmic preparations for ocular administration comprising 0.001-1%) by weight solutions or suspensions of the therapeutic compound of the present invention in an acceptable ophthalmic formulation may be used.
  • compositions which comprises a compound of the present invention and a pharmaceutically acceptable carrier.
  • composition is intended to encompass a product comprising the active ingredient(s), and the inert ingredient(s) (pharmaceutically acceptable excipients) that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients.
  • the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the present invention, additional active ingredient(s), and pharmaceutically acceptable excipients.
  • Any suitable route of administration may be employed for providing a mammal, especially a human with an effective dosage of a compound of the present invention.
  • oral, rectal, topical, parenteral, ocular, pulmonary, nasal, and the like may be employed.
  • Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, creams, ointments, aerosols, and the like.
  • compositions of the present invention comprise a compound of the present invention as an active ingredient or a pharmaceutically acceptable salt thereof, and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients.
  • pharmaceutically acceptable salts refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic bases or acids and organic bases or acids.
  • compositions include compositions suitable for oral, rectal, topical, parenteral (including subcutaneous, intramuscular, and intravenous), ocular (ophthalmic), pulmonary (aerosol inhalation), or nasal administration, although the most suitable route in any given case will depend on the nature and severity of the conditions being treated and on the nature of the active ingredient. They may be conveniently presented in unit dosage form and prepared by any of the methods well-known in the art of pharmacy.
  • the compounds of the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or nebulisers.
  • the compounds may also be delivered as powders, which may be formulated and the powder composition may be inhaled with the aid of an insufflation powder inhaler device.
  • the preferred delivery systems for inhalation are metered dose inhalation (MDI) aerosol, which may be formulated as a suspension or solution of a compound of the present invention in suitable propellants, such as fluorocarbons or hydrocarbons and dry powder inhalation (DPI) aerosol, which may be formulated as a dry powder of a compound of the present invention with or without additional excipients.
  • MDI metered dose inhalation
  • DPI dry powder inhalation
  • Suitable topical formulations include transdermal devices, aerosols, creams, ointments, lotions, dusting powders, and the like.
  • the compounds of the present invention can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques.
  • the carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous).
  • any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid preparations, such as, for example, suspensions, elixirs and solutions; or carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations such as, for example, powders, capsules and tablets, with the solid oral preparations being preferred over the liquid preparations. Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit form in which case solid pharmaceutical carriers are obviously employed.
  • tablets may be coated by standard aqueous or nonaqueous techniques.
  • the therapeutic compound of the present invention may also be administered by controlled release means and/or delivery devices such as those described in U.S. Pat. Nos. 3,845,770; 3,916,899; 3,536,809; 3,598,123; 3,630,200 and 4,008,719.
  • compositions of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient, as a powder or granules or as a solution or a suspension in an aqueous liquid, a non-aqueous liquid, an oil-in-water emulsion or a water-in-oil liquid emulsion.
  • Such compositions may be prepared by any of the methods of pharmacy but all methods include the step of bringing into association the active ingredient with the carrier, which constitutes one or more necessary ingredients.
  • compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation.
  • a tablet may be prepared by compression or molding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent.
  • each tablet contains from about 1 mg to about 500 mg of the active ingredient and each cachet or capsule contains from about 1 to about 500 mg of the active ingredient.
  • Compounds of the present invention may be used in combination with other drags that are used in the treatment/prevention/suppression or amelioration of the diseases or conditions for which compounds of the present invention are useful. Such other drags may be administered, by a route and in an amount commonly used therefor, contemporaneously or sequentially with a compound of the present invention, such as methimazole derivatives and tautomeric cyclic thiones.
  • a pharmaceutical composition containing such other drugs in addition to the compound of the present invention is preferred.
  • the pharmaceutical compositions of the present invention include those that also contain one or more other active ingredients, in addition to a compound of the present invention.
  • active ingredients that may be combined with a compound of the present invention I, either administered separately or in the same pharmaceutical compositions, include, but are not limited to: (a) VCAM-1 antagonists; (b) steroids such as beclomethasone, methylprednisolone, betamethasone, prednisone, dexamethasone, and hydrocortisone; (c) immunosuppressants such as cyclosporin, tacrolimus, rapamycin and other FK-506 type immunosuppressants; (d) antihistamines (HI -histamine antagonists) such as bromopheniramine, chlorpheniramine, dexchlorpheniramine, triprolidine, clemastine, diphenhydramine, diphenylpyraline, tripelennamine, hydroxyzine, methdilazine, promethazine, trim
  • the weight ratio of the therapeutic compound of the present invention to the second active ingredient may be varied and will depend upon the effective dose of each ingredient. Generally, an effective dose of each will be used. Thus, for example, when a therapeutic is combined with an NSAID the weight ratio of the compound of the therapeutic compound of the present invention to the NSAID will generally range from about 1000:1 to about 1 :1000, preferably about 200:1 to about 1:200. Combinations of a therapeutic and other active ingredients will generally also be within the aforementioned range, but in each case, an effective dose of each active ingredient should be used.
  • Pro-inflammatory cytokine e.g. TNF- ⁇
  • ECAMs endothelial cell adhesion molecules
  • HAEC human aortic endothelial cells
  • HBSS Balanced Salt Solution
  • Ca ++ and Mg " " 4" HBSS+
  • HBSS+ Biowhittaker
  • Delbecco's Phosphate Buffered Saline without Ca 4" or Mg ++ (PBS) is from KD Medical (Columbia, MD).
  • Heat inactivated defined fetal bovine serum (FBS) is from Hyclone Laboratories Inc. (Logan, UT).
  • L-glutamine, trypsin-versene, penicillin/streptomycin, and non-essential amino acid all are from Biosource International (Camarillo, CA).
  • Endothelial growth factor is from Calbiochem (San Diego, CA).
  • Bovine hypothalamus extract is from Pel-Freeze Biological Inc. (Rogers, AR). Gelatin, heparin, DMSO, BSA, O-phenylenediamine dihydrochloride (OPD) and phosphate citrate buffer tablets with sodium perborate are from Sigma Chemical Co. (St. Louis, MO). BSA is added to HBSS+ to generate a HBSS+, 0.5 % BSA assay buffer. Reeombinant human TNF - ⁇ is from Calbiochem. C-10 is synthesized as described by Ricerca (Cleveland, OH) (26). C-10 is prepared as 200 mM stock solution in DMSO.
  • Antibodies Function blocking murine mAb HEL3/2 (anti-human E- selectin; IgG is a generous gift from Dr. Raymond T. Camphausen (Wyeth Laboratories; Cambridge, MA). Function blocking murine mAb 51-10C9 (anti-human VCAM-1; IgG is from BD Pharmingen (San Diego, CA). Murine mAb R6.5 (anti-human ICAM-1; IgG 2a ) is kindly provided by Dr. Robert Rothlein (Boehringer fngelheim; Ridgefield, CT). Murine mAb TS1/22 (anti-human LFA-1; IgGi) is from Endogen (Woburn, MA).
  • HRP conjugated goat F(ab') 2 anti-mouse IgG polyclonal secondary antibody (Calbiochem) is used to detect the primary mAbs in the ELISA.
  • the polyclonal antibodies to p50 (sc-1191), p65 (sc-109), p52 (sc-298), c-rel (sc- 70), RelB (sc-226), IRF-1 (sc-1041X) are from Santa Cruz Biotechnology (Santa Cruz, CA).
  • HAEC Human aortic endothelial cells
  • Ml 99 supplemented with 8% FBS, 100 ⁇ g/ml heparin, 10 ng/ml endothelial growth factor, 100 ⁇ g/ml hypothalamus extract, 2 mM L- glutamine, 1% non-essential amino acids, 100 units/ml penicillin and 100 ⁇ g/ml streptomycin.
  • HAEC are subcultured on gelatin pre-coated: 96-well tissue culture plates (Corning Incorporated; Corning, NY) for viability assays and ELISA; 100-mm tissue culture dishes (BD Falcon; Franklin Lakes, NJ) for Northern blot analyses, Western blot analyses and EMSA; 35-mm tissue culture dishes (Corning) for adhesion assays and on 24-well tissue culture plates for luciferase promoter assays (BD Falcon). All experiments are performed with confluent HAEC monolayers. Unless noted otherwise, HAEC are treated with 25 ng/ml TNF- ⁇ , in the absence or presence of C-10 or 0.25% DMSO (carrier control for C-10), for 2 - 24 hrs.
  • the concentration of DMSO is held constant at 0.25% (unless indicated otherwise) for all of the C-10 conditions.
  • concentrations used in this study have little to no effect on HAEC viability as determined by MTS assay (20) and visual inspection of the HAEC monolayers (data not shown).
  • U937 cells (American Type Culture Collection; Manassas, VA) are cultured in RPMI supplemented with 8% FBS, 2 mM L-glutamine, 100 units/ml penicillin and 100 ⁇ g/ml streptomycin.
  • RPMI fetal bovine serum
  • U937 cells are washed, resuspended to lxl 0 8 cells/ml in RPMI and held on ice ( ⁇ 4 hrs.) until the time they are used in the flow adhesion assay.
  • ELISA is used to characterize the protein levels of ECAMs on HAEC in a manner similar to that described previously (20). HAEC are washed with cold HBSS+, fixed in 1% formaldehyde at 4 °C for 20 min., washed with cold HBSS+, and incubated in cold M199 containing 8% FBS. Unless otherwise noted, from this point on all antibody dilutions and washes are carried out with M199 containing 8% FBS. Murine mAbs (primary mAbs) to ECAMs are added (10 ⁇ g/ml) and the HAEC incubated at 4 °C for 20 min.
  • the wells are washed and a peroxidase conjugated polyclonal (secondary) antibody to mouse IgG is added (diluted 1:50). After a 20 min. incubation at 4 °C, the wells are washed and treated with OPD dissolved in phosphate citrate buffer containing sodium perborate. Following a 10 min. incubation at room temperature, the absorbance of the fluid in each well is determined at 450 nm using a micro-well plate spectrophotometer (Molecular Devices; Sunnyvale, CA). In every experiment, each condition is run in triplicate wells.
  • RNA isolation and Northern blot analysis is used to characterize the mRNA levels in a manner similar to that described previously (27, 29, 33). HAEC are washed with PBS and total RNA extracted using a commercial kit (RNeasy Mini Kit; Qiagen Inc.; Valencia, CA). 12 ⁇ g of total RNA per lane is resolved on 1% denaturing agarose gels containing 0.66M formaldehyde. Gels are capillary blotted on Nytran membranes (Schleicher and Schuell Inc.; Keene, NH), UV cross-linked, and used for hybridization. The probe for LRF-1 has been previously described (33).
  • the G3PDH cDNA is from Clontech (Palo Alto, CA). Other probe sequences are synthesized by RT-PCR (33) using the following cDNA specific primers: VCAM-1, 5'GACTCCGTCTCATTGACTTGCAGCACCACAG 3' and 5'ATACTCCCGCATCCTTCAACTGGGCCTTTCG 3' (1876bp); E-Selectin, 5'GTGCAGCCATTCCCCTGCTGGAGAGTTC 3' and 5'GGGCCAGAGACCCGAGGAGAGTTATCTG 3' (977bp); and ICAM-1, 5'CTCAGGTATCCATCCATCCCAGAGAAGCCTTCC 3' and 5'CCCTTGAGTTTTATGGCCTCCTCCTGAGCCTTC 3' (1514bp).
  • Nuclear Extracts and EMSA Nuclear extracts are prepared from harvested HAEC using NE-PER ® extraction reagents (Pierce Chemical Co.; Rockford, IL) in the presence of a protease inhibitor cocktail (PMSF, Leupeptin, Pepstatin-A).
  • Oligonucleotides (Biosynthesis Inc.; Lewisville, TX) are annealed and precipitated double stranded oligonucleotides end labeled with ⁇ - 32 P - ATP using T4 polynucleotide kinase enzyme. Binding reactions (20 min., room temperature) included P-labeled probe (activity 100,000 cpm), 3 - 6 ⁇ g HAEC nuclear extract, 1 ⁇ g poly(dl-dC), ImM DTT, 10% glycerol and IX binding buffer.
  • Binding buffer (10X) for NF- ⁇ B EMSA is 200 mM HEPES-KOH (pH7.9), 340 mM KC1, 50 mM MgCl 2 , 5 mM EDTA (pH 8.0), 1% Triton X-100.
  • Binding buffer (10X) for IRF-1 EMSA is 100 mM Tris-HCL (pH 7.5), 500 mM NaCl, 50 mM MgCl 2 , 10 mM EDTA (pH 8.0). h competition studies, nuclear extracts are incubated with 100 fold molar excess of unlabeled double stranded oligonucleotide.
  • Flow adhesion assays A parallel plate flow chamber (Glycotech; Rockville, MD), similar to that described by Mc tire, Smith and colleagues (34) is used in this study. Our particular set up has been described previously (20). A 35-mm tissue culture dish containing a confluent HAEC monolayer is loaded into the flow chamber. After a brief rinse, U937 cells (5 * 10 5 cells / ml in assay buffer) are drawn over the HAEC monolayer at a shear stress of 1.8 dynes/cm .
  • TNF- ⁇ activated HAEC in the absence or presence of C-10, are treated with mAbs HEL3/2 or 51-10C9 (10 ⁇ g/ml) or a combination of HEL3/2 and 51-10C9. The mAb treated HAEC are then mcubated at 37°C for 15 min. prior to use in adhesion assays.
  • Dual Luciferase Assay Four human VCAM-1 promoter deletion constructs of different length, -1641/+12, -288/+12, -228/+12, -85/+12 bp are amplified by PCR from human genomic DNA. Each upstream primer contained a restriction endonuclease Mlu I site located at the 5 '-end of the primer. The downstream primer corresponding to the +12 end contained a restriction endonuclease Xho I site at the 5 '-end.
  • PCR products are digested by Mlu I and Xho I (New England Biolabs Inc., Beverly, MA) and ligated into a similarly digested pGL3 basic luciferase reporter vector (Promega, Madison, WI).
  • Cells are transfected for 24 hrs. with 400 ng of indicated constracts, or pGL3 basic luciferase reporter vector as control, using GeneJuice transfection reagent (Novagen Inc., Madison, WI). All cells are also transfected with pliRL-TK (h t-) vector (Promega), which contains wildtype Renilla luciferase (Rluc) as an "internal" transfection control.
  • Luciferase assays are conducted with the Dual-Luciferase Reporter Assay System (Promega) on a Lumat LB 9507 tube luminometer. In every experiment, each condition is run in triplicate wells. Each experiment is replicated at least twice.
  • Methimazole derivatives and tautomeric cyclic thiones dramatically inhibit TNF-cc induced VCAM-1 expression-have a modest effect on E-selectin expression, and has no effect on ICAM-1 expression ]
  • endothelial cells e.g., HAEC. Since the ECAM profile on 4 hr. and 24 hr.
  • TNF- ⁇ treated endothelial cells is significantly different (6), we investigate the
  • HAEC protein expression on HAEC. Unactivated HAEC does not appear to express E-selectin or VCAM-1 but did express ICAM-1 (Fig. 1A). 4 hr. treatment of
  • TNF- ⁇ induced VCAM-1 mRNA expression has a
  • HAEC expresses elevated levels of ICAM-1 and VCAM-1 (relative to unactivated HAEC) (Fig. 2A). Treatment of HAEC with DMSO has little to no effect on
  • TNF- ⁇ induces expression of E-selectin, ICAM-1 and VCAM-1
  • TNF- ⁇ induces expression of E-selectin and VCAM-1 but has no effect
  • E-selectin and VCAM-1 mRNA while it has little to no effect on ICAM-1 mRNA expression (Fig. 2B).
  • the effect is not restricted to C 10 but is exemplified by other methimazole derivatives or tautomeric cyclic thiones.
  • Methimazole derivatives or tautomeric cyclic thiones e.g., CIO, inhibit monocytic cell adhesion to TNF- a activated HAEC
  • VCAM-1 has been shown to play a role in mononuclear leukocyte adhesion to vascular endothelium (35). This fact combined with our finding that C-10 significantly inhibits VCAM-1 protein expression (Figs. 1A and 2 A), led us to probe the effect of methimazole derivatives and tautomeric cyclic thiones on monocytic (U937) cell adhesion to 4 hr. and 24 hr. TNF- ⁇ activated HAEC.
  • TNF- ⁇ activated HAEC.
  • TNF- ⁇ activated HAEC A significant number of U937 cells adhered to 4 hr. TNF- ⁇ activated HAEC (column 2; Fig. 3 A) while very few, if any, U937 cells adhered to unactivated HAEC (column 1; Fig. 3 A). U937 cell adhesion is unaffected by treatment of 4 hr. TNF- ⁇ activated HAEC with 51-10C9, a function blocking mAb to VCAM-1 (column 3 vs. column 2; Fig.
  • TNF- ⁇ activated HAEC with HEL 3/2, a function blocking mAb to E-selectin (column 4 vs. column 2; Fig. 3A). Further reduction in U937 cell adhesion is seen upon treatment of 4 hr. TNF- ⁇ activated HAEC with a combination of 51-10C9 and HEL3/2 (column 5 vs. column 4; Fig. 3 A). Combined these results suggest that U937 cell adhesion to 4 hr. TNF- ⁇ activated HAEC is mediated by both E-selectin and VCAM-1. This is consistent with other reports (18).
  • TNF- ⁇ activation time point (Fig. 3B).
  • TNF- ⁇ activated HAEC (column 2; Fig. 3B) while very few, if any, U937 cells adhered to unactivated HAEC (column 1; Fig. 3B).
  • TNF- ⁇ activated HAEC is dependent on both E-selectin and VCAM-1 (column 5 vs. columns 2,3,4; Fig 3B).
  • the combination of C-10 and the mAb to E-selectin (HEL3/2) significantly reduced 24 hr.
  • TNF- ⁇ induced U937 cell adhesion (column 6 vs. column 2; Fig 3B).
  • C- 10 and the mAb to E-selectin significantly reduced the 24 hr.
  • TNF- ⁇ induced U937 cell adhesion relative to treatment with the mAb to E-selectin alone (column 6 vs. column 4; Fig 3B).
  • Treatment of HAEC with C-10 alone also significantly reduced the 24 hr.
  • TNF- ⁇ induced U937 cell adhesion relative to treatment with DMSO (column 7 vs. column 8; Fig 3B).
  • Methimazole derivatives or tautomeric cyclic thiones e.g., CIO effect VCAM-1 gene transcription
  • VCAM-1 transcriptional regulatory element Four truncations of the VCAM-1 transcriptional regulatory element are created (-1641/+12, -288/+12, -228/+12 and -85/+12 bp constracts) in an attempt to grossly separate their activities (Fig. 4). These are then inserted into a luciferase reporter plasmid and transfected into HAEC.
  • TNF- ⁇ treatment induces an increase in promoter activities of each of the four constracts (Fig. 4).
  • C-10 treatment inhibits the TNF- ⁇ induced activities of all four constructs (Fig. 4) in the absence of a consistent significant effect on basal promoter activity (Fig. 4). Note that although the TNF- ⁇ -induced increase in promoter activity decreases between the -228/+12 and -85/+12 bp constructs (Fig. 4), an inhibitory effect of C-10 is observed with the 85/+12 bp construct (Fig. 4).
  • Methimazole derivatives or tautomeric cyclic thiones do not affect TNF- a induced NF- B binding activity to VCAM-1 promoter ]
  • the binding sites for NF- ⁇ B, in the VCAM-1 promoter, are located
  • Antibodies directed against p50 are antibodies to various NF- ⁇ B subunits. Antibodies directed against p50 are antibodies to various NF- ⁇ B subunits. Antibodies directed against p50 are antibodies to various NF- ⁇ B subunits. Antibodies directed against p50 are antibodies to various NF- ⁇ B subunits. Antibodies directed against p50 are antibodies to various NF- ⁇ B subunits. Antibodies directed against p50
  • Methimazole derivatives or tautomeric cyclic thiones e.g., CIO, inhibit TNF-a induced IRF-1 binding activity to VCAM-1 promoter
  • CIO luciferase reporter assays suggestes that methimazole derivatives and tautomeric cyclic thiones affect a transcriptional regulatory event that occurs within -85/+12 bp in the VCAM-1 promoter (Fig. 4)
  • site for LRF-1 is located downstream of NF- B binding sites within the -
  • TNF- ⁇ induced VCAM-1 expression is a consequence of methimazole derivatives and tautomeric cyclic thiones inhibition of TNF- ⁇ induced IRF-1
  • EMSA activity we conduct EMSA. EMSA are performed with 32 P-labeled LRF-1
  • methimazole derivatives and tautomeric cyclic thiones reduce TNF- ⁇ induced
  • LRF-1 protein and mRNA expression are not restricted to CIO but is exemplified by other methimazole derivatives or tautomeric cyclic thiones.
  • C-10 a phenyl derivative of methimazole (a compound commonly used to treat autoimmune diseases, e.g. Graves' disease), has novel anti-inflammatory properties.
  • methimazole derivatives and tautomeric cyclic thiones dramatically inhibit TNF- ⁇ induced VCAM-1 mRNA and protein expression, have a relatively modest inhibitory effect on E-selectin expression and have no effect on ICAM-1 expression.
  • the effect on VCAM-1 inhibition is transcriptional and that methimazole derivatives and tautomeric cyclic thiones significantly reduce TNF- ⁇ induced monocytic cell adhesion to HAEC under in vitro flow conditions similar to that present in vivo.
  • both E-selectin and VCAM-1 have been shown to support tethering and rolling of lymphocytes (37, 38)) compounds that suppress the expression of several of the ECAMs maybe more effective at blocking leukocyte adhesion in a variety of inflammation settings.
  • methimazole derivatives and tautomeric cyclic thiones exert a greater inhibitory effect on TNF- ⁇ induced VCAM-1 expression as compared to the effect on E-selectin and ICAM-1 and can diminish monocytic cell adliesion to the endothelium under flow.
  • methimazole derivatives and tautomeric cyclic thiones inhibit TNF- ⁇ induced VCAM-1 expression in a NF- ⁇ B independent and an IRF-1 dependent manner. Further, methimazole derivatives and tautomeric cyclic thiones can also be used tools to probe the role of IRF-1 in gene regulation.
  • methimazole derivatives and tautomeric cyclic thiones exhibit anti-inflammation properties.
  • phenyl methimazole i) dramatically inhibits TNF- ⁇ induced VCAM-1 expression, has a modest inhibitory effect on E-selectin expression and has no effect on ICAM-1 expression on HAEC; (ii) significantly reduces TNF- ⁇ induced monocytic (U937) cell adhesion to HAEC under in vitro flow conditions similar to that present in vivo; (iii) inhibits TNF- ⁇ induced LRF-1 binding activity to VCAM-1 promoter and (iv) reduces TNF- ⁇ induced IRF-1 expression in HAEC.
  • methimazole derivatives and tautomeric cyclic thiones can be used as a therapeutic for the treatment of pathological inflammation, in particular diseases involving VCAM-1 (e.g., atherosclerosis and inflammatory bowel disease).
  • compositions in dosage unit form comprise an amount of composition which provides from about 0.05 to about 60 milligrams, preferably from about 0.05 to about 20 milligrams, of active compound per day.
  • Useful pharmaceutical formulations for administration of the active compounds of this invention may be illustrated below. They are made using conventional techniques.
  • This tablet can be sugar coated according to conventional art practices. Colors may be added to the coating.
  • Spl is a component of the cytokine-inducible enhancer in the promoter of vascular cell adhesion molecule- 1. JBiol Chem 270:28903-28909.
  • Endothelial interferon regulatory factor 1 cooperates with NF-kappa B as a transcriptional activator of vascular cell adhesion molecule 1. Mol Cell Biol 15:2558-2569.
  • VCAM-1 vascular cell adhesion molecule-1
  • Methimazole protects from experimental autoimmune uveitis by inhibiting antigen presenting cell function and reducing antigen priming. JLeukoc Biol 73:57-64.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

La présente invention concerne de nouveaux composés et des techniques d'utilisation permettant d'inhiber et de prévenir l'adhésion cellulaire et les pathologies induites par l'adhésion cellulaire. Cette invention concerne aussi des préparations pharmaceutiques comprenant ces composés et des techniques d'utilisation de ces préparations en vue d'inhiber et de prévenir l'adhésion cellulaire et les pathologies induites par l'adhésion cellulaire. Les composés et les compositions pharmaceutiques de cette invention peuvent être utilisés comme agents thérapeutiques ou prophylactiques. En particulier des dérivés de méthimazole et des thiones cycliques tautomères possèdent la capacité d'inhiber l'adhésion et la migration de leucocytes. Outre le fait d'être des anti-inflammatoires actifs, les dérivés de méthimazole et les thiones cycliques tautomères et des sels, des dérivés et des promédicaments de ceux-ci répondant aux normes physiologiques, conviennent généralement pour le traitement (par exemple pour la thérapie et la prophylaxie) de maladies fondées sur l'interaction entre VCAM-1 et ses ligands ou peuvent être influencés par une inhibition de cette interaction. En particulier des dérivés de méthimazole et des thiones cycliques tautomères conviennent pour le traitement de maladies causées au moins partiellement par une extension indésirable de l'adhésion de leucocytes et/ou de la migration de leucocytes ou connectées à ces phénomènes, et dont la prévention, l'atténuation ou le traitement implique une diminution de l'adhésion et/ou de la migration des leucocytes.
EP04821836A 2004-03-16 2004-03-16 Derives de methimazole et thiones cycliques tautomeres pour inhiber l'adhesion cellulaire Withdrawn EP1725230A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2004/007888 WO2005094819A1 (fr) 2004-03-16 2004-03-16 Derives de methimazole et thiones cycliques tautomeres pour inhiber l'adhesion cellulaire

Publications (2)

Publication Number Publication Date
EP1725230A1 true EP1725230A1 (fr) 2006-11-29
EP1725230A4 EP1725230A4 (fr) 2009-08-19

Family

ID=35063499

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04821836A Withdrawn EP1725230A4 (fr) 2004-03-16 2004-03-16 Derives de methimazole et thiones cycliques tautomeres pour inhiber l'adhesion cellulaire

Country Status (5)

Country Link
EP (1) EP1725230A4 (fr)
JP (1) JP2007529510A (fr)
AU (1) AU2004317993A1 (fr)
CA (1) CA2559712A1 (fr)
WO (1) WO2005094819A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
US7928132B2 (en) * 2004-08-06 2011-04-19 Ohio University Methods for the amelioration of episodes of acute or chronic ulcerative colitis
WO2015066490A1 (fr) 2013-10-31 2015-05-07 Ohio University Prévention et traitement de stéatose hépatique non alcoolique
CN106659714B (zh) 2014-07-18 2021-06-08 俄亥俄大学 用于改变生物信号传导的咪唑和噻唑组合物
SG11201706706XA (en) 2015-02-20 2017-09-28 Wisconsin Alumni Res Found Generating arterial endothelial cell populations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012175A2 (fr) * 1998-08-31 2000-03-09 Sentron Medical, Inc. Derives de methimazole et thiones cycliques tautomeres permettant de traiter les maladies auto-immunes
US6365616B1 (en) * 1998-08-31 2002-04-02 Sentron Medical, Inc. Methimazole derivatives and tautomeric cyclic thiones to treat autoimmune diseases
WO2004017962A2 (fr) * 2002-08-26 2004-03-04 S.L.A. Pharma Ag Composition pharmaceutique

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002505288A (ja) * 1998-03-02 2002-02-19 コセンシス，インコーポレイテッド 置換キナゾリンおよびアナログならびにそれらの使用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012175A2 (fr) * 1998-08-31 2000-03-09 Sentron Medical, Inc. Derives de methimazole et thiones cycliques tautomeres permettant de traiter les maladies auto-immunes
US6365616B1 (en) * 1998-08-31 2002-04-02 Sentron Medical, Inc. Methimazole derivatives and tautomeric cyclic thiones to treat autoimmune diseases
WO2004017962A2 (fr) * 2002-08-26 2004-03-04 S.L.A. Pharma Ag Composition pharmaceutique

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AL MOUTAERY A: "Methimazole prevents stress and chemical induced gastropathy in rats" EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY, JENA, DE, vol. 55, no. 4, 2003, pages 277-285, XP004956131 ISSN: 0940-2993 *
ISMAN C A ET AL: "Methimazole-induced hypothyroidism in rats ameliorates oxidative injury in experimental colitis." JOURNAL OF ENDOCRINOLOGY, vol. 177, no. 3, June 2003 (2003-06), pages 471-476, XP009057654 ISSN: 0022-0795 *
OREN B ET AL: "Anti-thyroid drugs decrease mucosal damage in a rat model of experimental colitis" ALIMENTARY PHARMACOLOGY AND THERAPEUTICS, vol. 11, no. 2, 1997, pages 341-345, XP009057663 ISSN: 0269-2813 *
See also references of WO2005094819A1 *
SINGER DINAH S ET AL: "Methimazole prevents induction of experimental systemic lupus erythematosus in mice" JOURNAL OF IMMUNOLOGY, vol. 153, no. 2, 1994, pages 873-880, XP002356401 ISSN: 0022-1767 *

Also Published As

Publication number Publication date
AU2004317993A1 (en) 2005-10-13
EP1725230A4 (fr) 2009-08-19
WO2005094819A1 (fr) 2005-10-13
CA2559712A1 (fr) 2005-10-13
JP2007529510A (ja) 2007-10-25

Similar Documents

Publication Publication Date Title
CN111039944B (zh) Mst1激酶抑制剂及其用途
US7183285B2 (en) Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7928132B2 (en) Methods for the amelioration of episodes of acute or chronic ulcerative colitis
ES2403558T3 (es) Inhibidores purínicos y pirimidínicos de CDK y su uso para el tratamiento de enfermedades autoinmunitarias
US20110046119A1 (en) Therapeutic treatment
JP2021193105A (ja) Ｅｔｃ１００２及びエゼチミブを含む固定用量組合せ物及び製剤並びに心血管疾患を処置するか又は心血管疾患のリスクを低減させる方法
US20210069184A1 (en) Methods and compositions for prevention and treatment of cardiac hypertrophy
US11737993B2 (en) Multiple myeloma treatment
US7163945B2 (en) Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7199126B2 (en) Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20110190324A1 (en) Methods of treating atherosclerosis
US20050209295A1 (en) Methimazole derivatives and tautomeric cyclic thiones to inhibit cell adhesion
WO2005094819A1 (fr) Derives de methimazole et thiones cycliques tautomeres pour inhiber l'adhesion cellulaire
EP2694074B1 (fr) Utilisation d'antagonistes de récepteur d'adénosine a2b pour traiter l'insuffisance cardiaque et l'arythmie chez des patients post-infarctus du myocarde
JP2021535136A (ja) 心血管疾患及び関連する状態を有する患者を処置するための併用薬製剤
US20110118276A1 (en) Methods of treating atherosclerosis
WO2018057933A1 (fr) Composés, compositions et procédés pour réduire le stress oxydatif dans les cardiomyocytes
UA81290C2 (en) Use of telmisartan and simvastatin, pharmaceutical composition and treatment method
WO2015160696A1 (fr) Compositions et procédés d'inhibition d'histone désacétylases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060918

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20090720

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/4164 20060101AFI20090714BHEP

Ipc: A61P 1/04 20060101ALI20090714BHEP

17Q First examination report despatched

Effective date: 20091208

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110211